MSMadeleine O. Saunders

Madeleine O. Saunders

*This is an algorithmically generated author record based on publicly available information.

Madeleine O. Saunders has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiplexed single-tier immunoassay for improved Lyme disease diagnosis across all disease stages

    by Phillip Stafford, Holly Ahern, John Aucott, Alison Rebman, Elizabeth J. Horn, Marianne Hathaway, Madeleine Saunders, Nicole R. Hasenkampf, Monica E. Embers

    Lyme disease is the most common vector-borne infection in North America and Europe, yet current two-tier serologic testing shows poor sensitivity during early infection when antibiotic treatment is most effective. We developed and validated a single-tier multiplex immunoassay that combines ten Borrelia burgdorferi antigens with machine-learning classification to detect antibody responses across all disease stages. A total of 364 cases were obtained, which included well characterized prospective blood samples obtained during early infection. In a cohort of samples from the Johns Hopkins University SLICE studies, the classifier identified all 30 early Lyme disease cases and their 1–3-month post-treatment follow-up samples. To assess generalizability, an independent EU laboratory synthesized the antigens de novo and a distinct 259-person cohort was evaluated on newly built assays. The classifier achieved an AUC of 0.98 in both cohorts. This single-test platform delivers quantitative serologic classification using standard clinical laboratory instrumentation, addressing critical gaps in Lyme disease diagnosis.


  • Open Access

    Activity in the Ventral Medial Prefrontal Cortex Is Necessary for the Therapeutic Effects of Extinction in Rats

    by Elizabeth A. Fucich, Denisse Paredes, Madeleine O. Saunders, David A. Morilak

    Poor response and high relapse rates remain problematic in the treatment of stress-related psychiatric disorders such as depression and post-traumatic stress disorder. Although mechanisms of pharmacotherapies are intensely studied, little is known about mechanisms of behavioral therapy that could inform improved treatments. We have previously demonstrated the therapeutic effects of extinction learning as a behavioral intervention modeling exposure therapy in rats. In the present study, we tested the hypothesis that activity in the ventral medial prefrontal cortex (vmPFC) during extinction is necessary for its therapeutic effects. The inhibitory Gi-coupled designer receptor exclusively activated by designer drug CaMKIIα-hM4Di was expressed in vmPFC before administering chronic unpredictable stress (CUS). vmPFC projection neurons were then inhibited during extinction treatment by administering clozapine-N-oxide. Coping behavior and cognitive flexibility were assessed 24 h later on the shock-probe defensive burying test and attentional set-shifting test, respectively. Replicating previous results, extinction reversed the CUS-induced deficits in coping behavior and cognitive flexibility. Inhibiting vmPFC during extinction blocked these therapeutic effects. Further, increasing vmPFC activity with the excitatory Gq-coupled designer receptor exclusively activated by designer drug hM3Dq 24 h before testing was sufficient to reverse the CUS-induced deficits. CUS reduced mPFC responsivity, assessed by measuring afferent-evoked field potentials in the mPFC, and this reduction was reversed by extinction treatment 24 h before testing. These results demonstrate the necessity of vmPFC activity in the therapeutic effects of extinction as a model of exposure therapy, and suggest that increased vmPFC activity induced by extinction is sufficient to produce lasting plastic changes that underlie its beneficial effects.SIGNIFICANCE STATEMENTStress-related psychiatric disorders remain poorly treated. Psychotherapies can be effective, but their mechanisms remain unknown, hindering progress toward improved treatment. We used a rat model of behavioral therapy to identify potential targets for enhancing treatment. Fear extinction as a therapeutic behavioral intervention reversed stress-induced cognitive dysfunction and passive coping in rats, modeling components of stress-related psychiatric disease. Extinction also reversed stress-induced attenuation of mPFC responsivity. The therapeutic effects were prevented by blocking activity of glutamatergic neurons in the mPFC during extinction, and were mimicked by inducing activity in lieu of extinction. Thus, activity and plasticity in the mPFC underlie the beneficial effects of extinction on cognitive flexibility and coping behavior compromised by stress, and could be targets to enhance behavioral therapy.